Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


From Big Data To Cybersecurity, Today’s Device-Makers Face Myriad Compliance Risks – But Being Proactive Can Pay Off, Ex-FDA Official Says

Too many medical device manufacturers are struggling because they don’t have policies and systems in place to handle the ever-growing amount of data they receive about their products once they’ve gone to market.

As a result, important signals can go undetected or unaddressed, leading to compliance problems and devices that are of poor quality – both of which could ultimately affect a device-maker’s bottom line. But Ricki Chase, a former US FDA investigations branch director, says firms can nip those troubles in the bud by being more proactive in their approach to tackling incoming quality data.

"Because the world has become so connected and everything has become so digitized, there’s just an enormous amount of data out there for firms to collect," said Chase, now a compliance practice director for Lachman Consultant Services Inc. She joined Lachman in 2016 after spending 16 years at FDA, where she was also an investigator, medical device specialist and supervisory investigator.

"From data being shared on personal-use devices to medical devices being linked to a telemetry hub in a hospital setting, to devices that are speaking to doctors directly so they can monitor you remotely – the data is just incredible," Chase said. "But the problem with having that amount of data out there is, manufacturers aren’t necessarily able to get their arms around it and understand what may be going on with their devices, and what may be impacting their performance."

Such an avalanche of data can throw a company’s key performance indicators (KPIs) for a loop. KPIs are used to measure a company’s success; for device-makers, one KPI might be how quickly they can send product to market, while another might gauge how devices are performing in the field.

For instance, "people go online and will say, ‘I used this product and it burned me,’ or ‘This device shocked me.’ That now becomes data that should be considered by a firm to be an event or complaint," Chase said. "But the problem is, a lot of times it’s anecdotal information that’s being collected. And there’s a lot of it."

Because that type of data can be unreliable, a manufacturer can’t be wholly sure that its KPI for complaint handling is accurate. "The sheer volume of data out there makes it really difficult for firms to keep their key performance indicators precise, timely and in line," she said.

Chase strongly urges companies to think more proactively by developing procedures to help them manage the increased regulatory risk posed by big data collection.

A lack of adequate policies to address the issue is "probably the No. 1 failure you see when device firms get into trouble with FDA, or end up having large market withdrawals or recalls," she said. "By nature, many people who work in a regulated area can be reactive rather than proactive. And when you’re dealing with something like the large amount of data that’s out there revolving around your device or your quality system, you must have systems designed and in place to be able to capture, design control changes is another story," Chase said.

"But where firms can get in trouble is when they buy 510(k) devices, because the owner of the 510(k) only had to show substantial equivalence to gain access to the market. At no time did they have to submit that design to the FDA for review," she said. "And it’s not until post-market inspection that you might find out that the design control either wasn’t done originally, or it was done but it wasn’t done well, or it was done but it’s so old that all of the design changes that have occurred since then have not been incorporated anywhere."

After two manufacturers finally come together, the acquiring firm will typically fire the other company’s top leaders, an action that Chase advises firms to handle with caution. "When that happens, now there are a bunch of people at the acquired firm that are the worker bees that are very unfamiliar with their new leaders, whom they’re supposed to trust to lead them down the right path," she said. "Something like that can be a real culture shift for people, and can be extremely challenging."

The acquiring manufacturer also must decide how to best integrate quality systems, and to do it right.

"I’ve seen this happen frequently: You end up acquiring a company. You now have multiple sites. They all kind of do the same thing. Now they’re all under one umbrella, but each of the locations is working under a different quality system – and they’re all commonly owned," Chase said, noting that it can become "extremely complicated" for a firm in such a position to know what’s happening systemically across its entire organization.

"And remember, at the end of the day the corporate entity is ultimately responsible for all of its sites. So, it can be very, very challenging to manage those locations when they’re all so vastly different," she said.

A union between companies can also prove challenging when it comes to developing standard operating procedures and quality systems that are unique to the activities of specific facilities. "It’s never one-size-fits-all," Chase said. "So, there’s always going to be work to be done, whether you’re trying to marry those quality systems, create a whole new quality system, or overcome the differences between the quality systems."

Investing In Quality Is Always A Wise Decision

In the end, device-makers can manage their many regulatory risks by having a robust, well-resourced strategy for compliance in place, as well as a healthy quality system.

"If you construct your quality system and your compliance strategy properly from the beginning, and you seriously invest and think about quality as an investment, then your firm will be more successful," Chase said. "It has been proven time and time again that investing in quality saves companies money in the long run. That’s because being reactive to problems – particularly serious problems – costs firms tons of money in reputation, in product, in downtime and in diverted resources – resources that now must be used to remediate, not to mention having to hire a third-party to come into your facility and help you. It can be very, very expensive."

To catch the attention of top management, Chase suggests that quality and regulatory professionals place a dollar amount on the value of good, thorough quality.

"At most companies, quality is an afterthought, when it should be the first thought," she said. "It really starts with the management, and understanding that leadership comes from the top, and that they have to set the tone. If they set the tone that quality is first and foremost, and they create a system to be successful in that realm, then products do come to market faster. They generally come to market faster because a good quality system will identify problems early on and will help you correct problems the first time so you’re not continually going back and fixing the same problems."

If using the persuasiveness of the purse strings doesn’t work, those in quality and regulatory should make it personal for management.

"When I talk to senior leaders about investing in quality, I try to explain to them, or ask them, or converse with them: ‘Why did you get into the industry in the first place? Why are you in the position you’re in? What is your goal? And what do you think would make your company more profitable?’ And then when they tell me what they think would make them be more profitable, I always try to link that back to a quality component, Chase said.

And if that still doesn’t change top management’s mind, then they should be reminded that their own job security is at stake if quality systems are poor.

The Bottom Line

"The medical device industry is growing very quickly. But it’s not only growing quickly; it’s becoming more and more technologically advanced, too. And because the technology is becoming so complex, there is increased risk to your devices and to your company with regard to your compliance," Chase said in summation.

"The expectation is that your firm will keep pace with industry developments and with the expectations for maintaining current good manufacturing practices," she said. "It’s not just a matter of keeping pace and becoming more technologically advanced; it’s also a matter of understanding what the different expectations are because of that, and what FDA’s expectations are, and how you adjust – and how you can do that proactively, because being proactive reduces your compliance cost and can increase your bottom line."

All original content reproduced herein is the exclusive property of Lachman Consultant Services, Inc. protected under copyright and other intellectual property laws. Not to be Reproduced or Disseminated without Express Permission.

©2017 Lachman Consultant Services, Inc.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts